September 27, 2014
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which crizotinib is highly active. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Shaw et al. (Sat,) studied this question.
synapsesocial.com/papers/69d7dab7ec32c73b01ae30bf — DOI: https://doi.org/10.1056/nejmoa1406766
Authors
Alice T. Shaw
Université Paris-Sud
S
Sai‐Hong Ignatius Ou
University of California, Irvine
Yung‐Jue Bang
Rutgers, The State University of New Jersey
Journals
New England Journal of Medicine
Actions
Institutions
University of Chicago
Massachusetts General Hospital
Dana-Farber Cancer Institute
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...